not used title

not used title

Today PhRMA joins with innovators around the globe to recognize World IP Day and celebrate biopharmaceutical innovators who dedicate their lives to bringing new treatments and cures to patients. It’s also a day to reflect on the role Intellectual Property (IP) protections, such as patents, play in supporting the development of cutting-edge technologies.  

This year’s theme is “Women and IP: Accelerating innovation and creativity,” which is a celebration of the drive and perseverance of women inventors, creators and entrepreneurs around the world. The life sciences industry — which includes biopharmaceutical companies, medical device companies and diagnostics firms — is now nearly 50% female (up from just 34% in 1990) and home to the greatest proportion of woman innovators named on U.S. patents.  

PhRMA spoke with several women leaders in IP and innovation at biopharmaceutical companies to let them share in their own words why protecting IP rights is so important and what gives them hope for the next generation of female innovators.  

Xiaorong He is senior vice president, site head of Development U.S., and head of Global Development Sciences at Boehringer-Ingelheim, and she is named on multiple patents. Xiaorong shared with us, “as a Chinese woman working in the pharmaceutical industry in the 1990s, I felt like a unicorn, but I also felt like being both a woman and a minority was an advantage because I had such a unique perspective. Over the last 20 years, I have seen more and more women and minorities come to our field because of efforts around diversity, equity and inclusion. As more diverse creators get a seat at the table, we must ensure that we have a strong IP system in place so those innovators can apply science to make an impact for patients.”  

Andrina Zink, executive director of Alkermes’ Intellectual Property practice and the author of seven scientific publications, also spoke with us from her perspective as a mother and female leader. Andrina shared, “being a patent attorney and a mother is a balance but also gives me hope for the future. My 16-year-old daughter asked me the other day, if she became president, what women’s rights issue should she focus on? After a bit of research, we decided the issue was clearly education. Even though we have made great strides, women are still underrepresented in STEM, which is what leads to innovation. As we continue to focus on getting more women involved in STEM and reducing barriers to entry, we must also ensure that there are strong IP protections in place that support and protect their ideas.”  

Michelle Garnsey, senior principal scientist at Pfizer, led a group of over 30 scientists in the discovery and synthesis of a first-in-class small molecule, which is in clinical testing for malnutrition of aging where no approved therapies are currently available. She shared with us that early in her career there were times where she hesitated to speak up in meetings with colleagues. “So, when I think about my career path and my hope for the next generation of women, I hope that we get to a place where we are enabling young women in our field to have the confidence to speak up, show passion, and be their authentic selves at work. When I think about the role of patents and IP in this discussion, it starts with making sure that the next generation of female inventors get the same opportunities to protect their inventions,  because without patent protection, sustainable innovation just isn’t viable.”  

As all three women pointed out, despite the progress for women that we have seen over the past several decades, our work is not finished. The biopharmaceutical industry will continue our sustained commitment to supporting STEM education, closing the gender gap in innovation, strengthening and diversifying our workforce, and preserving our IP system to ensure protections are there for the next generation of female inventors and leaders.  

Megan Van Etten

Megan Van Etten is Vice President of Public Affairs. She is responsible for leading the association’s public affairs efforts on international issues, including trade, intellectual property and access to medicines. Prior to joining PhRMA, Megan was director of media and external communications at the U.S. Chamber of Commerce and communications director at the Beer Institute. She has also worked as a communications consultant for global public relations firms. When not at the office, Megan enjoys exploring new Washington, D.C. restaurants and traveling with her husband and friends.

Megan Van Etten

Recognizing the transformative impact of intellectual property

October 13, 2026

Bayh-Dole: The fuel for America’s innovation engine

September 2, 2026

ICYMI: Biopharmaceutical companies in America hit new investment milestone

August 14, 2026

Setting the record straight: 3 facts about drug patents

July 13, 2026

New PBM principles don't change the fundamental challenge: Access to lower-cost medicines

July 10, 2026

Staffing up: Building the future biopharma workforce to keep America in the lead

June 29, 2026

World Sickle Cell Day: Recognizing the promise of gene therapy

June 19, 2026

MFN could disrupt the affordable medicines patients depend on

June 18, 2026

Nearly 80 researchers advocate on Capitol Hill

June 11, 2026

Intellectual Property and Hatch-Waxman: A blueprint for American leadership and patient savings

June 2, 2026

America's cancer research progress is real and worth protecting

May 28, 2026

Ahead of ASCO: Cancer innovation is promising, but policy choices matter

May 26, 2026

Argentina sets course to enable innovation by rejecting failed patent rules

March 26, 2026

16 years later: How BPCIA continues to expand competition and lower costs

March 23, 2026

Key context is often missing from the debate over the Patent Trial and Appeal Board

March 20, 2026

How AI is transforming the drug innovation lifecycle

March 19, 2026

MFN undermines U.S. biopharmaceutical innovation

February 25, 2026

Updated Analysis Underscores the Need for Brazil to Address Patent Backlogs

February 2, 2026

Congratulations to our 2026 Working for Cures Employee Champions

January 29, 2026

How post-approval innovation keeps delivering for patients

December 9, 2025

PhRMA calls on USTR to ensure foreign nations pay their fair share

November 4, 2025

Three things to know about Bayh-Dole: Innovation that pays off for taxpayers

October 9, 2025

Manufacturing U.S. jobs and breakthroughs

October 6, 2025

Historic biopharmaceutical investments: A prescription for America’s future

September 29, 2025

Delivering breakthroughs and lower costs for patients

September 8, 2025

PBMs, not patents, are blocking access to lower-cost medicines

July 23, 2025

Bringing to life the full story of biopharmaceutical innovation and investments

July 22, 2025

New report: How intellectual property drives U.S. innovation and biopharma's impact

June 30, 2025

What to know about vaccine ingredients: Aluminum and thimerosal

June 24, 2025

Americans are paying a 26% freerider tax on medicines because other countries don’t pay their fair share

June 17, 2025

PhRMA Foundation celebrates 60 years of investing in future scientific leaders

June 11, 2025

New report: Post-approval innovation delivers substantial patient benefits

June 2, 2025

The biopharmaceutical industry is one of the highest contributors to America’s economy among all manufacturers

April 30, 2025

USTR 2025 Special 301 Report corrects course

April 29, 2025

From sound to science: How IP powers innovation in music and hearing

April 25, 2025

How the IRA is impacting the generic drug market

April 8, 2025

3 myths critics get wrong about intellectual property

March 28, 2025

ICYMI: PhRMA submits comments to White House on artificial intelligence

March 17, 2025

4 things to know on Rare Disease Day

February 28, 2025

Biopharmaceutical innovation for a healthier America: PhRMA releases new innovation report

February 21, 2025

New policy agenda charts solutions for a healthier America

February 20, 2025

A successful PhRMA Forum highlights our commitment to a healthier America

February 20, 2025

Guest Perspective: Prioritize Innovative Care

February 11, 2025

Preventing and fighting disease: A look at the biopharmaceutical progress made for patients in 2024

February 3, 2025

A new administration poses new opportunities for patient access

December 17, 2024

Recognizing the value of disease prevention with Dr. Len Friedland from GSK

December 12, 2024

Congratulations to our 2024 Working for Cures Employee Champions

December 11, 2024

Post-approval R&D is critical for fighting cancer. The IRA makes it more difficult.

November 13, 2024

PhRMA submission calls for USTR to correct course on trade policy, enforcement

October 18, 2024

The importance of partnership: A conversation with Takeda

October 10, 2024

New Report: Tackling chronic conditions with preventive treatment

September 30, 2024

40 Years of Hatch-Waxman: How Can We Secure its Legacy?

September 24, 2024

40 Years of Hatch-Waxman: How does the Hatch-Waxman Act help patients?

September 23, 2024

Addressing the mounting threat of antimicrobial resistance

September 23, 2024

40 Years of Hatch-Waxman: What is the Hatch-Waxman Act?

September 19, 2024

New research: American biopharmaceutical investment in R&D drives transformational innovation

September 16, 2024

Biden Administration report debunks myths around patent “evergreening” and “thickets”

September 3, 2024

How to protect your children’s health this school year

August 22, 2024

What to know about the latest effort to break patents using a legally dubious avenue

August 21, 2024

WTAS: Proposed Unsubstantiated USPTO Rule Change is a Threat to American Innovation

August 12, 2024

Industry-backed STEM programs have supported 111 million students and nearly 183,000 teachers

August 1, 2024

Three things to know about the United Nations’ new HIV/AIDS report

July 31, 2024

New Report: Vaccines continue to drive improved health outcomes

July 16, 2024

The future of oncology R&D lies in policymakers’ hands

July 8, 2024

More than 60 researchers advocate on Capitol Hill

July 1, 2024

Showcasing the promise of biopharma at ASCO 2024

June 28, 2024

Alzheimer's & Brain Awareness Month: A conversation with Biogen

June 27, 2024

PhRMA launches education campaign on the benefits of America's IP system

June 26, 2024

Alzheimer's & Brain Awareness Month: A conversation with Eisai

June 24, 2024

Alzheimer's & Brain Awareness Month: A conversation with Eli Lilly and Company

June 20, 2024

ICYMI: Misaligned policies undermine patient access

June 6, 2024

Women’s Health Month: A conversation with Astellas

May 31, 2024

ICYMI: Innovation transforms lives but misguided federal policies threaten patient outcomes

May 30, 2024

Experts discuss the value of IP at Senate Judiciary Committee hearing

May 28, 2024

Mental Health Awareness Month: Supporting loved ones and improving mental health in America

May 28, 2024

Women’s Health Month: A conversation with Sage

May 23, 2024

World Trade Week 2024: Time for a more ambitious U.S. trade agenda

May 23, 2024

The use of real-world data in drug development

May 13, 2024

New analysis: Accelerated approval pathway is changing lives in underserved communities

April 30, 2024

World IP Day 2024: Supporting an innovative and sustainable future

April 26, 2024

World Vaccine Congress: Building on vaccine success

April 1, 2024

The impact of innovative medicines: A caregiver's perspective

March 26, 2024

ICYMI: More evidence of the IRA’s harmful consequences on post-approval research and development

March 25, 2024

What new cures would mean to families

March 7, 2024

Watch: A conversation with Dr. Mike Ybarra on Rare Disease Day

February 29, 2024

American Heart Month: A nurse’s perspective

February 27, 2024

International meetings hold big implications for Americans and our innovation ecosystem

February 26, 2024

Proposed march-in framework would chill American innovation

February 7, 2024

Three things to know about antibody drug conjugates

February 2, 2024

PhRMA 2024 Special 301 submission: USTR needs to support American innovation, global access to medicines

January 31, 2024

Powering the next generation of therapies: A conversation with Astellas US President Mark Reisenauer

January 30, 2024

New poll: Americans agree that expanding the TRIPS waiver will harm U.S. global manufacturing and innovation leadership

January 29, 2024

What they are saying: Experts agree that proposed march-in framework would jeopardize innovation

January 25, 2024

Novel treatments and vaccines approved for U.S. patients in 2023 reach five-year high

January 23, 2024

When it comes to the future of innovation, the ball is in policymakers’ court

January 22, 2024

The Biopharmaceutical Industry Still Needs Clarity from the FDA on Orange Book Listings

December 19, 2023

The White House continues to attack American innovation

December 15, 2023

Taking stock of obesity and its costly effects

December 8, 2023

Congratulations to our 2023 Working for Cures Employee Champions

December 6, 2023

Watch: Putting patients front and center for World AIDS Day

November 30, 2023

Biden Administration’s Indo Pacific trade dialogue is a missed opportunity to bolster American exports, innovation

November 29, 2023

Misuse of march-in could stifle innovation

November 27, 2023

WHO Pandemic Agreement offers opportunities and risks for American innovators

November 20, 2023

The IRA’s pill penalty threatens the future of oncology R&D

November 16, 2023

Don't close the door on rare disease research

November 13, 2023

New Report: 1,600 cancer treatments and vaccines in clinical development

November 9, 2023

Word of the Month: The Bayh-Dole Act

November 8, 2023

ICYMI: 3 takeaways on the IRA’s unintended consequences from America’s Physician Groups’ 2023 annual fall conference

November 6, 2023

PhRMA submission: USTR needs more ambition to combat unfair trade barriers

October 24, 2023

R&D leaders to Biden Administration: Your policies are undermining the Cancer Moonshot

October 18, 2023

Three things economists are saying about the Inflation Reduction Act

October 11, 2023

Celebrating Hispanic Heritage Month at PhRMA

October 11, 2023

Word of the Month: AMR

September 27, 2023

It’s PBMs, not patents, blocking competition 

September 14, 2023

What you need to know: COVID-19 public health emergency is over, but ideological attacks on IP remain

September 12, 2023

New PhRMA site demonstrates how a technology-driven health care system brings benefits to patients

September 11, 2023

Watch: New video series spotlights advances in biopharmaceutical science

August 24, 2023

Decentralized clinical trials and the future of drug development

August 9, 2023

WTAS on reasonable pricing and public-private partnerships

August 8, 2023

Key considerations as Congress works towards PAHPA reauthorization

July 12, 2023

New report shows high-impact R&D happens after cancer medicines are first approved

July 10, 2023

More than 60 researchers ask Congress to support innovation

June 26, 2023

New report shows how the Inflation Reduction Act stifles innovation for small molecule medicines

June 22, 2023

Biopharmaceutical science powered by PRIDE

June 16, 2023

ASCO 2023: Protecting our progress in the fight against cancer

June 15, 2023

Reject efforts to undermine America’s R&D ecosystem

June 15, 2023

Highlights from ASCO 2023

June 8, 2023

Addressing Mental Health: A conversation with Barry Greene, CEO of Sage Therapeutics

May 30, 2023

Four ways that America’s biopharmaceutical industry supports jobs and fuels economic growth

May 18, 2023

Mental Health Awareness Month: Fighting the growing mental health crisis and supporting innovation

May 11, 2023

Setting the record straight on the Bayh-Dole Act and March-in

May 10, 2023

Support for continued progress is critical for pediatric drug development

May 8, 2023

New resource underscores the importance of small molecule medicines

May 4, 2023

Policies need to address the growing threat of antimicrobial resistance

April 28, 2023

CMS guidance on IRA price setting process doubles down on bad policy

April 14, 2023

A guide to MedPAC’s Part B vote today

April 13, 2023

What they are saying: Experts reinforce that TRIPS waiver expansion is harmful and unnecessary

April 13, 2023

New global analysis shows patient access challenges around the world

April 12, 2023

ICYMI: PhRMA President and CEO Stephen J. Ubl discusses patient affordability

April 7, 2023

PhRMA provides comments and testimony to USITC investigation on COVID-19 medicines and the TRIPS Agreement

March 30, 2023

New Report: More than 400 medicines in development for leading chronic conditions affecting older Americans

March 28, 2023

Celebrating the success of the COVID-19 vaccines, and looking to the future

March 27, 2023

IRA Impacts: Cancer treatment research and development

March 23, 2023

PhRMA submits comments to OSTP on enhancing clinical trial diversity

March 21, 2023

U.S. biopharmaceutical exports support jobs, innovation

March 20, 2023

What we’ve learned from three years of fighting COVID-19

March 20, 2023

Will the administration capitalize on the Indo-Pacific Economic Framework to drive medical innovation?

March 13, 2023

Celebrating 40 years of the Orphan Drug Act on Rare Disease Day

February 28, 2023

PhRMA submits comments to USPTO highlighting important role of patent system in medicine development

February 23, 2023

State policymakers can protect American innovation and help Americans live longer, healthier lives

February 9, 2023

U.S. must address IP and market access barriers abroad to protect American innovation

January 31, 2023

Novel medicines approved in 2022 offer increased treatment options for patients

January 23, 2023

ICYMI: PhRMA kicks off the year at the 2023 J.P. Morgan Health Care Conference

January 19, 2023

Biden administration should prioritize innovation in U.S.-Taiwan Initiative on 21st-Century Trade

January 17, 2023

WTAS: Inflation Reduction Act already impacting R&D decisions

January 17, 2023

Sparking conversations — and careers — at the 2nd annual Pathways to Success Summit

December 8, 2022

Stories from the lab: Researchers discuss innovative treatments for cancers of the blood

December 1, 2022

Expanding TRIPS waiver would jeopardize biopharmaceutical research and development

November 17, 2022

Six ways I-MAK is lying about biopharma patents

November 16, 2022

TRIPS waiver expansion risks public health

November 14, 2022

Congratulations to our 2022 Working for Cures Employee Champions

November 10, 2022

New government price setting policy threatens post-approval research

November 10, 2022

Expanding the WTO intellectual property waiver will hurt American jobs

November 9, 2022

ICYMI: PhRMA COO Lori Reilly Esq. speaks with Jacob Van Naarden about the future of cancer research

November 8, 2022

New paper: Addressing the growing crisis of mental health and substance use disorders

November 7, 2022

PhRMA submission to USTR calls for urgent defense of American innovation abroad

November 1, 2022

Protecting treatment advances for breast cancer

October 31, 2022

The law driving technology transfer and fostering innovation

October 24, 2022

Don’t take anti-innovation, activist funded academics at their word

October 18, 2022

Protecting against influenza: A conversation with David Ross, Vice President, Commercial Operations, North America, CSL Seqirus

October 13, 2022

Mental Illness Awareness Week – A time for reflection

October 3, 2022

New report ignores benefits of patent system to innovation and patients

September 30, 2022

New Report: Nearly 800 medicines in development to treat chronic conditions

September 29, 2022

Recognizing National Sickle Cell Awareness Month

September 23, 2022

Partnerships are driving global COVID-19 treatment access

September 22, 2022

ICYMI: New research builds upon growing body of evidence on value of COVID-19 treatments and vaccines

August 16, 2022

This week’s reading list: All the reasons the Senate-passed drug pricing bill is bad policy

August 10, 2022

Myth vs. Fact: The Senate’s latest price setting proposal

August 5, 2022

An open letter to Congress: Stand with patients and future cures

August 4, 2022

The Senate’s latest price setting proposal will undermine U.S. economic growth

August 3, 2022

New analysis finds deeper impact of drug pricing bill on biopharmaceutical researchers

August 1, 2022

ICYMI: A patient, physician, biotech investor and industry leaders warn about the dangers of government price setting bill

July 29, 2022

The Senate’s latest price setting proposal will undermine: American medical innovation

July 27, 2022

Patent policy changes proposed by USPTO and FDA would leave patients behind

July 22, 2022

PhRMA member companies’ R&D investments reach record high of $102.3 billion in 2021

July 18, 2022

ICYMI: PhRMA’s Ubl pens op-ed on IP waiver for COVID-19 technologies

July 15, 2022

Increase in drug-resistant superbugs during COVID-19 highlights need for policy reforms to address antimicrobial resistance

July 14, 2022

Word of the Month: Biomarkers and surrogate endpoints

July 11, 2022

COVID-19 vaccines and treatments helped save millions of lives and billions in health care costs

July 7, 2022

CMS coverage decision restricts access to treatments for Alzheimer’s disease

June 22, 2022

Key takeaways from ASCO's annual meeting

June 10, 2022

Biopharmaceutical researchers to discuss the value of R&D with Congress

June 9, 2022

Recognizing LGBTQ+ Pride in biopharmaceutical science

June 9, 2022

Intellectual Property waiver on COVID-19 innovation is unnecessary and harmful

May 23, 2022

Report: More than 500 medicines in development to treat disorders of the blood

May 18, 2022

Ensuring timely reauthorization of PDUFA and BsUFA

May 11, 2022

ICYMI: PhRMA COO Lori Reilly spotlights efforts to improve health care in 2022 and beyond

May 9, 2022